Navigation Links
Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Date:8/23/2007

coplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's operations and financial condition, business objectives and strategic goals, drug development plans, and the efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of t
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... --  Heska Corporation (NASDAQ: HSKA ) - ... advanced veterinary diagnostic and other specialty veterinary products , ... attend The Benchmark Company, LLC,s Micro Cap Discovery Conference on ... at The Palmer House Hilton, 17 E. Monroe Street, ... p.m. Please email hska@haydenir.com or contact your Benchmark ...
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... As annual open enrollment season begins for ... are available to answer questions and provide guidance ... 15 to December 7, Medicare beneficiaries have the ... enroll in a new plan, if they so ...
... Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the ... treatment of Alzheimer,s and other neurological diseases today issued ... Chairman and CEO. Dear Shareholder, ... you about pertinent corporate and industry developments contemporaneous with ...
Cached Medicine Technology:CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period 2Intellect Neurosciences Issues Letter to Shareholders 2Intellect Neurosciences Issues Letter to Shareholders 3Intellect Neurosciences Issues Letter to Shareholders 4Intellect Neurosciences Issues Letter to Shareholders 5Intellect Neurosciences Issues Letter to Shareholders 6Intellect Neurosciences Issues Letter to Shareholders 7Intellect Neurosciences Issues Letter to Shareholders 8Intellect Neurosciences Issues Letter to Shareholders 9
(Date:11/27/2014)... DressVe , the well-known trendy young women’s clothing retailer, ... during Nov. 29 – Dec. 3 2014. In the special ... to 90% off. In addition, free delivery is provided for ... http://www.dressve.com/ , Dresses that combine trendy styles and high ... personality and figure. The designers of DressVe.com know this point ...
(Date:11/27/2014)... November 28, 2014 Cyber Monday cannot ... Turks & Caicos. This boutique resort, ranked #1 ... announcing a few highly sought out openings before Christmas ... they are offering every seventh night complimentary if booked ... is having a January 2015 promotion where every fourth ...
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
Breaking Medicine News(10 mins):Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... ... , ... 2010 -- From self-published author Felicia J. Henderson comes a personal tale of despair, survival, ... book that will reach out to those who have experienced life’s trials and never lost ...
... ... volcano Eyjafjallajökull has not only interfered in the air traffic around the globe. ... the important booking season for tourism to Iceland, it has affected the bookings ... only seen few requests on holiday offers since the eruption had started and ...
... Calif.) Extremely obese children have a 40 percent ... who are moderately obese have a 30 percent higher ... to a Kaiser Permanente study published online in the ... large population-based study establishes an association between obesity and ...
... ... three dental programs in the nation to receive the “Best Practice” award from Safety Net ... have translated into positive improvements for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s ...
... ... Patient Care , ... NY (Vocus) July 8, 2010 -- As nursing assumes an increasingly prominent role in the ... announced today it will soon require newly hired nurses to have a Bachelor of Nursing ...
... USA (July 8, 2010) To provide authors additional ... abstracts is now extended until July 31 for the ... held December 2-4 at the Washington Marriott Hotel in ... symposium on the following five topics: "Virus biology," "Pandemics, ...
Cached Medicine News:Health News:Self-Published Author Shares Her Personal Story of Hope Amidst Despair 2Health News:Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland" 2Health News:Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland" 3Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 2Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 3Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree 2Health News:North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree 3Health News:Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010 2
... automated, easy to operate and maintain. The ... by flexible snap-seal pockets which minimize the ... of the water. Offered in two-, four-, ... accommodate bags of various sizes. ThermoLine Thawing ...
Inquire...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
... This test device is intended ... of IgG and IgM antibodies ... serum. The test is used ... diagnosis of Dengue viral infection ...
Medicine Products: